Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Commentary
  • Published:

Postgenomic prospects of success in drug development and pharmacotherapy

The Pharmacogenomics Journal volume 1, pages 6–9 (2001)Cite this article

The human genome has now been mapped by virtue of enormous academic and financial investments over the past decade.1,2 We now know the dimension of the genome which contains about 30 000 identified genes and 3.5 billion base pairs.

This marks the start of the new era of functional genomics including pharmacogenomics. The latter term denotes the influence of genetic variation on the disposition of drugs, as well as the response and adverse reactions to drugs.

This is a preview of subscription content, access via your institution

Access options

References

  1. International Human Genome Sequencing Consortium . Initial sequencing and analysis of the human genome Nature 2001 409: 860–921

    Article  Google Scholar 

  2. Gerlach JH et al . The sequence of the human genome Science 2000 291: 1304–1351

    Google Scholar 

  3. Bray D . Reductionisms for biochemists: how to survive in the protein jungle Trends Biochem Sci 1997 22: 325–330

    Article  CAS  Google Scholar 

  4. The International SNP Map Working Group . A map of human genome sequence variation containing 1.4 million single nucleotide polymorphisms Nature 2001 409: 928–933

    Article  Google Scholar 

  5. Evans WE, Relling MV . Pharmacogenomics: translating functional genomics into rational therapeutics Science 1999 286: 487–491

    Article  CAS  Google Scholar 

  6. Mahgoub A, Idle JR, Dring DG, Lancaster R, Smith RL . Polymorphic hydroxylation of debrisoquine in man Lancet 1997 2: 584–586

    Google Scholar 

  7. Eichelbaum J, Spannbrucker N, Steinke B, Dengler HJ . Defective N-oxidation of sparteine in man: a new pharmacogenetic defect Eur J Clin Pharmacol 1979 16: 183–187

    Article  CAS  Google Scholar 

  8. Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J . Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodyanamics of tolterodine Clin Pharmacol Ther 1998 63: 529–539

    Article  CAS  Google Scholar 

  9. Mortimer Ö et al. Polymorphic formation of morphine from codeine in poor and extensive metabolisers of dextromethorphan. Relationship to the presence of immunoidentified cytochrome P-450IID1 Clin Pharmacol Ther 1990 47: 27–35

    Article  CAS  Google Scholar 

  10. Gerlach JH et al . Genetic analysis of the Chinese CYP2D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation Mol Pharmacol 1994 46: 452–459

    Google Scholar 

  11. Wadelius M, Darj E, Frenne G, Rane A . Induction of CYP2D6 in pregnancy Clin Pharmacol Ther 1997 62: 400–407

    Article  CAS  Google Scholar 

  12. Gerlach JH et al . Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 2000 97: 3473–3478

    Article  Google Scholar 

  13. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Makowicz SB . Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Nat Canc Inst 1998 90: 1225–1229

    Article  CAS  Google Scholar 

  14. Gerlach JH et al . Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness Proc Natl Acad Sci USA 2000 97: 10483–10488

    Article  Google Scholar 

  15. Lazarou J, Pomeranz BH, Corey PN . Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies JAMA 1998 279: 1200–1205

    Article  CAS  Google Scholar 

  16. Gerlach JH et al . An information-intensive approach to the molecular pharmacology of cancer Science 1997 275: 343–349

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden

    A Rane

Authors
  1. A Rane
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Rane.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rane, A. Postgenomic prospects of success in drug development and pharmacotherapy. Pharmacogenomics J 1, 6–9 (2001). https://doi.org/10.1038/sj.tpj.6500013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500013

This article is cited by

Search

Advanced search

Quick links